NASDAQ:INZY

Inozyme Pharma Competitors

$15.49

+0.30 (+1.97 %)

(As of 05/14/2021 12:49 PM ET)

Add

Compare

Today's Range

$15.43

▼

$15.97

50-Day Range

$15.85

▼

$21.20

52-Week Range

$14.51

▼

$31.65

Volume1,468 shs

Average Volume57,213 shs

Market Capitalization$363.61 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Inozyme Pharma (NASDAQ:INZY) Vs. KRON, AUPH, PRLD, CMPS, PMVP, and INVA

Should you be buying INZY stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Inozyme Pharma, including Kronos Bio (KRON), Aurinia Pharmaceuticals (AUPH), Prelude Therapeutics (PRLD), COMPASS Pathways (CMPS), PMV Pharmaceuticals (PMVP), and Innoviva (INVA).

Inozyme Pharma vs. Kronos Bio Stock

Kronos Bio (NASDAQ:KRON) and Inozyme Pharma (NASDAQ:INZY) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.

Profitability

This table compares Kronos Bio and Inozyme Pharma's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kronos Bio	N/A	N/A	N/A
Inozyme Pharma	N/A	N/A	N/A

Institutional and Insider Ownership

69.8% of Inozyme Pharma shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Kronos Bio and Inozyme Pharma's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kronos Bio	N/A	N/A	N/A	N/A	N/A
Inozyme Pharma	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent ratings and recommmendations for Kronos Bio and Inozyme Pharma, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kronos Bio	0	0	4	0	3.00
Inozyme Pharma	0	0	4	0	3.00

Kronos Bio presently has a consensus price target of $43.6667, indicating a potential upside of 66.86%. Inozyme Pharma has a consensus price target of $36.00, indicating a potential upside of 132.26%. Given Inozyme Pharma's higher possible upside, analysts clearly believe Inozyme Pharma is more favorable than Kronos Bio.

Summary

Inozyme Pharma beats Kronos Bio on 2 of the 2 factors compared between the two stocks.

Inozyme Pharma vs. Aurinia Pharmaceuticals Stock

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Inozyme Pharma (NASDAQ:INZY) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends and valuation.

Profitability

This table compares Aurinia Pharmaceuticals and Inozyme Pharma's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	-173,992.23%	-36.98%	-31.06%
Inozyme Pharma	N/A	N/A	N/A

Institutional & Insider Ownership

51.2% of Aurinia Pharmaceuticals shares are held by institutional investors. Comparatively, 69.8% of Inozyme Pharma shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Aurinia Pharmaceuticals and Inozyme Pharma's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$320,000.00	4,768.50	$-123,850,000.00	($0.89)	-13.38
Inozyme Pharma	N/A	N/A	N/A	N/A	N/A

Inozyme Pharma has lower revenue, but higher earnings than Aurinia Pharmaceuticals.

Analyst Recommendations

This is a summary of recent recommendations for Aurinia Pharmaceuticals and Inozyme Pharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0	0	7	0	3.00
Inozyme Pharma	0	0	4	0	3.00

Aurinia Pharmaceuticals presently has a consensus target price of $28.00, indicating a potential upside of 135.10%. Inozyme Pharma has a consensus target price of $36.00, indicating a potential upside of 132.26%. Given Aurinia Pharmaceuticals' higher probable upside, analysts clearly believe Aurinia Pharmaceuticals is more favorable than Inozyme Pharma.

Summary

Inozyme Pharma beats Aurinia Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

Inozyme Pharma vs. Prelude Therapeutics Stock

Prelude Therapeutics (NASDAQ:PRLD) and Inozyme Pharma (NASDAQ:INZY) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends and valuation.

Profitability

This table compares Prelude Therapeutics and Inozyme Pharma's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Prelude Therapeutics	N/A	N/A	N/A
Inozyme Pharma	N/A	N/A	N/A

Institutional & Insider Ownership

76.2% of Prelude Therapeutics shares are held by institutional investors. Comparatively, 69.8% of Inozyme Pharma shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Prelude Therapeutics and Inozyme Pharma's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prelude Therapeutics	N/A	N/A	N/A	N/A	N/A
Inozyme Pharma	N/A	N/A	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent recommendations for Prelude Therapeutics and Inozyme Pharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prelude Therapeutics	0	3	2	0	2.40
Inozyme Pharma	0	0	4	0	3.00

Prelude Therapeutics presently has a consensus target price of $55.80, indicating a potential upside of 33.52%. Inozyme Pharma has a consensus target price of $36.00, indicating a potential upside of 132.26%. Given Inozyme Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Inozyme Pharma is more favorable than Prelude Therapeutics.

Summary

Inozyme Pharma beats Prelude Therapeutics on 3 of the 4 factors compared between the two stocks.

Inozyme Pharma vs. COMPASS Pathways Stock

COMPASS Pathways (NASDAQ:CMPS) and Inozyme Pharma (NASDAQ:INZY) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends and valuation.

Earnings & Valuation

This table compares COMPASS Pathways and Inozyme Pharma's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
COMPASS Pathways	N/A	N/A	$-19,610,000.00	N/A	N/A
Inozyme Pharma	N/A	N/A	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent recommendations for COMPASS Pathways and Inozyme Pharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
COMPASS Pathways	0	0	7	0	3.00
Inozyme Pharma	0	0	4	0	3.00

COMPASS Pathways presently has a consensus target price of $70.80, indicating a potential upside of 108.54%. Inozyme Pharma has a consensus target price of $36.00, indicating a potential upside of 132.26%. Given Inozyme Pharma's higher probable upside, analysts clearly believe Inozyme Pharma is more favorable than COMPASS Pathways.

Profitability

This table compares COMPASS Pathways and Inozyme Pharma's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
COMPASS Pathways	N/A	N/A	N/A
Inozyme Pharma	N/A	N/A	N/A

Institutional & Insider Ownership

15.8% of COMPASS Pathways shares are held by institutional investors. Comparatively, 69.8% of Inozyme Pharma shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Inozyme Pharma beats COMPASS Pathways on 2 of the 3 factors compared between the two stocks.

Inozyme Pharma vs. PMV Pharmaceuticals Stock

Inozyme Pharma (NASDAQ:INZY) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, dividends and risk.

Earnings and Valuation

This table compares Inozyme Pharma and PMV Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inozyme Pharma	N/A	N/A	N/A	N/A	N/A
PMV Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Inozyme Pharma and PMV Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inozyme Pharma	0	0	4	0	3.00
PMV Pharmaceuticals	0	1	3	0	2.75

Inozyme Pharma currently has a consensus target price of $36.00, indicating a potential upside of 132.26%. PMV Pharmaceuticals has a consensus target price of $38.00, indicating a potential upside of 19.05%. Given Inozyme Pharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe Inozyme Pharma is more favorable than PMV Pharmaceuticals.

Profitability

This table compares Inozyme Pharma and PMV Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Inozyme Pharma	N/A	N/A	N/A
PMV Pharmaceuticals	N/A	N/A	N/A

Institutional and Insider Ownership

69.8% of Inozyme Pharma shares are owned by institutional investors. Comparatively, 69.7% of PMV Pharmaceuticals shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Inozyme Pharma beats PMV Pharmaceuticals on 4 of the 4 factors compared between the two stocks.

Inozyme Pharma vs. Innoviva Stock

Inozyme Pharma (NASDAQ:INZY) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, dividends and risk.

Earnings and Valuation

This table compares Inozyme Pharma and Innoviva's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inozyme Pharma	N/A	N/A	N/A	N/A	N/A
Innoviva	$261.02 million	4.96	$157.29 million	$1.43	8.94

Innoviva has higher revenue and earnings than Inozyme Pharma.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Inozyme Pharma and Innoviva, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inozyme Pharma	0	0	4	0	3.00
Innoviva	1	0	0	0	1.00

Inozyme Pharma currently has a consensus target price of $36.00, indicating a potential upside of 132.26%. Innoviva has a consensus target price of $10.00, indicating a potential downside of 21.88%. Given Inozyme Pharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe Inozyme Pharma is more favorable than Innoviva.

Profitability

This table compares Inozyme Pharma and Innoviva's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Inozyme Pharma	N/A	N/A	N/A
Innoviva	67.16%	53.99%	28.92%

Institutional and Insider Ownership

69.8% of Inozyme Pharma shares are owned by institutional investors. Comparatively, 71.5% of Innoviva shares are owned by institutional investors. 0.3% of Innoviva shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Innoviva beats Inozyme Pharma on 6 of the 9 factors compared between the two stocks.